Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NURO the next low float monster gem after OXBT and OXGN
Here are the fundamentals :
Trading below Cash
Revenue $5.4 M
Shares out 2.99 M
Float 1.8 M
Cash $7.7 M
Burn-rate 700k per Quarter
OXGN start moving like OXBT guys
Unknown Gem with Brutal Upside Potential ...GLTA
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $27 M
Cash: $3 M
Price:0.52
Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
Unknown Gem with Brutal Upside Potential ...GLTA
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $27 M
Cash: $3 M
Price:0.52
Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
Unknown Gem with Brutal Upside Potential ...GLTA
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $27 M
Cash: $3 M
Price:0.52
Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
IGXT = 1000%++ Potential
Unknown Gem with Brutal Upside Potential.... Thank me later !!!
2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .
NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)
Only 20 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA
Intelgenx (IGXT)
Market Cap : $27 M
Cash: $3 M
Price:0.52
Burn-Rate : $2 M a year
Shares Out : 51 M ( 30 M shares are held by Investors )
IGXT´s Monster Pipeline :
Product ......Application......... Status of Development
INT0004/2006 Antidepressant -- US launch in 4Q 2012
INT0008/2007 Migraine -- PDUFA Date on Feb 3 2014
INT0007/2006 Erectile Dysfunction -- NDA filing lin early 2014
INT0001/2004 CHF (Coronary Heart Failure), Hypertension -- ANDA filing in early 2014
INT0027/2011 Undisclosed Partnered with Par Pharma -- ANDA under review by FDA
INT0020/2010 Insomnia -- in Pivotal Study
INT0024/2010 Idiopathic pulmonary fibrosis -- in Pivotal Study
INT0028/2011 Cancer pain (cannabinoid) --in Pivotal Study
INT0030/2011 Animal health -- in Pivotal Study
INT0031/2012 Benign prostatic hyperplasia --in Pivotal Study
More good news out today ... Now they have 13 Products awaiting FDA approval .GL
IGI Laboratories, Inc. Announces Thirteenth ANDA Submission
http://finance.yahoo.com/news/igi-laboratories-inc-announces-thirteenth-123000375.html
Great results, great management , full pipeline with 12 products awaiting FDA approval everything is fantastic here .GL
Ticker ( IG )
Market Cap : $86 M
Cash : $2.3 M
Price : $2
Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M
IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "Our team has done a tremendous job this quarter. This quarter marks the fifth consecutive quarter of top line growth. Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters. We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013." Mr. Grenfell-Gardner continued, "Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve. Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million. Our team is committed to our plan to file at least six ANDAs in 2013. We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013."
Brutal Underpriced Gem..
Redhill Biopharma (RDHL)
Market Cap: $60 M
Cash: $14.7 M
Burn-rate : ~$10 per Year
Shares Out: 6.3 M ( Management holds over 2.6 M shares )
Float: 4 M
RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*
RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**
RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**
RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*
RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012
RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*
RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*
RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion
Good News ..
RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase III Study - to Commence Shortly
Press Release: RedHill Biopharma Ltd. – 28 minutes ago
http://finance.yahoo.com/news/redhill-biopharma-announces-fda-acceptance-120000067.html
Major Breakout to $15++ imminent guys ..Buy before the invesotrs discovers this low float Goldmine .GL
The Company’s current product pipeline includes:
RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*
RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**
RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**
RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*
RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012
RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*
RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*
RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion*
Load up this dirt cheap stock before it gets discovered ..
RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M
RDHL is another brutally Underpriced and Unknown Biotech Stock .
Here are the reasons why this low float Gem is a MUST HAVE for every Biotech investor :
1) Very Promising Pipeline with multiple potential Blockbusters
2) FDA decision for first Drug (migraine) on February 3
3) Another 2x NDA Filings soon one in 1Q and one in 2H 2014
4) Another 2 Drugs in Phase 3
5) Very low Burn-rate of only $10 M per year
6) Enough Cash untill mid 2015 Excluding cash from new Partnerships
7) Dirt Cheap with a Market cap of just $61 M
8) Ultra low float with only 4.2 M shares
9) Top Management ( they have one of the most successful director in the pharma area on their board , see below the info to this guy )
I think this low float stock has everything to hit minimum $50++ within 2014 .For me RDHL is currently my top favorite stock in the Biotech sector . GL
Redhill (RDHL)
Market Cap: $61 M
Cash: $14.7 M
Price: $9.80
Shares Out: 6.3 M (Management alone holding over 2.6 M shrs)
Float: 4.2 M
Presentation September 2013
http://files.shareholder.com/downloads/AMDA-1C0OBF/2736607566x0x690006/36cdf135-d2c9-4ce8-88d4-df998ade2152/RedHill%20Biopharma%20Presentation%20September%202013.pdf
Dan Suesskind, Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva’s board of directors.
RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M
RDHL is another brutally Underpriced and Unknown Biotech Stock .
Here are the reasons why this low float Gem is a MUST HAVE for every Biotech investor :
1) Very Promising Pipeline with multiple potential Blockbusters
2) FDA decision for first Drug (migraine) on February 3
3) Another 2x NDA Filings soon one in 1Q and one in 2H 2014
4) Another 2 Drugs in Phase 3
5) Very low Burn-rate of only $10 M per year
6) Enough Cash untill mid 2015 Excluding cash from new Partnerships
7) Dirt Cheap with a Market cap of just $61 M
8) Ultra low float with only 4.2 M shares
9) Top Management ( they have one of the most successful director in the pharma area on their board , see below the info to this guy )
I think this low float stock has everything to hit minimum $50++ within 2014 .For me RDHL is currently my top favorite stock in the Biotech sector . GL
Redhill (RDHL)
Market Cap: $61 M
Cash: $14.7 M
Price: $9.80
Shares Out: 6.3 M (Management alone holding over 2.6 M shrs)
Float: 4.2 M
Presentation September 2013
http://files.shareholder.com/downloads/AMDA-1C0OBF/2736607566x0x690006/36cdf135-d2c9-4ce8-88d4-df998ade2152/RedHill%20Biopharma%20Presentation%20September%202013.pdf
Dan Suesskind, Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva’s board of directors.
HIHO /Book Value $3.22 per shr/ Only 2.2 M shr on the float / Profitable
This is a very Speculative Play which is close to a major breakout and which could run like VISN (chart below) because of their ultra low float .
http://finance.yahoo.com/q/bc?s=VISN&t=1m&l=on&z=l&q=l&c=
Ticker : HIHO
Market Cap : $10.4 M
Cash : $4.7 M
Price $2.75
Shares Out : 3.7 M
Float: 2.2 M
This unknown Gem looks fantastic on all fronts and i will be not surprised to see this low float rocket flying close to 10 bucks or higher . This is a MEGA buying opp and im sure it will fly once the investors discover this Goldmine .
-
Buy Rating
The company's strengths can be seen in multiple areas, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and impressive record of earnings per share growth.
EDAP (MC $56 M) FDA approval for Prostate Cancer Cure in 1Q 2014 =500%++ Potential !!!
A LIFETIME OPPRTUNITY HERE GUYS ...Your opp to load up before the Investors discover this Goldmine !
This Undiscovered Gem is brutally Cheap and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .
FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA
EDAP
Market Cap: $56 M
Cash: $10 M
Price: $2,60
DEBT FREE
Shares Out: 21,7 M
Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.
Interview with CEO (Sept.25)
http://www.equities.com/media-gallery/188-edap-tms-s-a-nasdaq-edap?category_id=67
EDAP seeks FDA approval of its Ablatherm HIFU treatment for prostate cancer
EDAP (MC $56 M) FDA approval for Prostate Cancer Cure in 1Q 2014 =500%++ Potential !!!
A LIFETIME OPPRTUNITY HERE GUYS ...Your opp to load up before the Investors discover this Goldmine !
This Undiscovered Gem is brutally Cheap and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .
FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA
EDAP
Market Cap: $56 M
Cash: $10 M
Price: $2,50
DEBT FREE
Shares Out: 21,7 M
Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.
Interview with CEO (Sept.25)
http://www.equities.com/media-gallery/188-edap-tms-s-a-nasdaq-edap?category_id=67
EDAP seeks FDA approval of its Ablatherm HIFU treatment for prostate cancer
EDAP (MC $56 M) FDA approval for Prostate Cancer Cure in 1Q 2014 =500%++ Potential !!!
A LIFETIME OPPRTUNITY HERE GUYS ...Your opp to load up before the Investors discover this Goldmine !
This Undiscovered Gem is brutally Cheap and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .
FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA
EDAP
Market Cap: $56 M
Cash: $10 M
Price: $2,50
DEBT FREE
Shares Out: 21,7 M
Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.
Interview with CEO (Sept.25)
http://www.equities.com/media-gallery/188-edap-tms-s-a-nasdaq-edap?category_id=67
EDAP seeks FDA approval of its Ablatherm HIFU treatment for prostate cancer
ALIM is high risk investment because they need a lot money in the short term .
PSDV has many Products in late stage compared to ALIM thats why its the better Stock .
Please stop the ALIM pump here or i remove these postings .
test
test
test
test
Once it breaks $5 then most institutional investors who cant invest in stocks under $5 will jump in that means a run into double digits is possible IF approved .GL
Reiterate Buy rating and $7.00 PT for IPCI based on the expected launch of Focalin XR.
Attractive Focalin XR Economics to IPCI – Potential to Reach Breakeven: The 5mg, 10,mg, 15mg and 20mg doses of Focalin XR had combined 2012 branded sales of $643M. IPCI has partnered with Par Pharmaceutical for the launch of Focalin XR. Our forecast calls for Par and IPCI to recognize gross sales of $35M-40M over the initial six months with 75% gross margins and a long term gross margin of 45% once additional competitors enter the market. Our model assumes IPCI recognizing 30% of gross profit as revenue. Based on this forecast we believe the launch of Focalin XR may allow IPCI to approach cash flow breakeven and provide a solid base for future profitability based on approval of additional ANDA filings for sustained release generics.
Fantastic News out today and in the last few days the CEO is doing really a good job here . Dont forget his main goal is the Nasdaq Listing within 2014 and a requirement to get the Nasdaq Listing is the Stock must be above $3 so it means that he sees this stock moving higher than $3 which would mean a low market cap of around $54 Million .GL
Current Price : $1.05
--
Innovus Pharma Readies the Launch of EjectDelay(TM) for Premature Ejaculation With Nationwide Sampling Program to Urologists in the U.S. Through the American Urology Association...Sept. 24, 2013
http://finance.yahoo.com/news/innovus-pharma-readies-launch-ejectdelay-103000781.html
Innovus Pharma Signs Second License and Distribution Agreement With Ovation Pharma for EjectDelay(TM) in Morocco
Company to Receive Up to $18.6 Million in Payments
http://finance.yahoo.com/news/innovus-pharma-signs-second-license-103000740.html
Innovus Pharma Signs License and Distribution Agreement With Ovation Pharma for CIRCUMserum(TM) in Morocco
Company to Receive up to $11.25 Million in Milestone Payments
http://finance.yahoo.com/news/innovus-pharma-signs-license-distribution-103000358.html
Bid at $2.50 in Canada = US $2.42
http://www.stockhouse.com/Companies/Quote/t.i/intellipharmaceutics-international-inc
hey guys im the bernstein poster on yahoo need some poster there too . It doesnt look good as the only poster there hehe
8 drugs awaiting FDA approval many of them will be on the market within 5-8 months and another Big Potential Blockbusters will enter Phase 3 early 2014 all these for a laughable market cap of $47 Million .
I know almost all biotechs which listed on Nasdaq and OTC and i can say that IPCI is one of the most undervalued Bio stock out there but im sure that this will change very soon .
IPCI is defintely the next Billion Dollar Company in the making .
2k holding ??? muhahahahaha please dont buy so much bill gates
Each of these drug in the pipeline is worth more than current market cap especially the 2 potential Blockbuster these two MEGA drugs are worth minimum $200 M .
We just need one approval and then this low float rocket will fly fast .
Shareholders should put high sell GTC order for their shares this helps to reducse the free shares from the market which means bigger jumps for IPCI . TIA
IPCI is currently the cheapest Biotech Gem out there ..
Alone Focalin is worth more than current laughable market cap of $40 M .
This Sleeping Giant will awake very soon .
Another BUY rating by Brean Capital (Sep 13.)
http://breancapital.com/pdf/researchuniverse.pdf
Intellipharmaceutics Intl.
IPCI Buy $2.00 -- TGT $7.00 by Aschoff
hey guys where are you ?? you missing one of the biggest opp in this year
A close over $4 would be very bullish
Guys get in before its too late
I expect a runup to around $5 and a $1-2 jump on Approval day
Possible Breakout today ..Not many shares available on the Ask below $4 ..